

aero therapeutics



Aero Therapeutics selected for JLABS @ San Diego

February 2nd 2021

San Diego, CA - Aero Therapeutics Inc is pleased to announce that in January 2021 it began its residency at Johnson & Johnson Innovation – [JLABS @ San Diego, a premier life science incubator program](#).

“We are very excited to begin our journey as a startup company at Johnson & Johnson Innovation -JLABS. Where better to do this than right here in San Diego – a city with such a robust ecosystem for medical device innovation.” said Jamison Langguth, CEO of Aero Therapeutics.

Johnson & Johnson Innovation - JLABS is a global network of open innovation ecosystems, established with the aim to help enable and empower innovators across a broad healthcare spectrum including pharmaceutical, medical device, consumer and health tech sectors who strive to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients and consumers around the world.

Every breath matters.

Aero Therapeutics is an early-stage medical device company. Aero’s first device is a self-sterilizing high-flow respirator designed for extremely low resource settings. Prior to the pandemic, respiratory distress was responsible for 3.2% of all neonatal deaths in America, as well as affecting over 200K adult Americans per year. 1 out of 10 babies are born premature in America; the more premature the birth the more likely the newborn will need respiratory support. Despite advances in mechanical support and evolving concomitant surfactant therapies, neonatal respiratory distress (NRDS) remains lethal worldwide. For more information please visit www.BreatheAero.com.